HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

AbstractOBJECTIVE:
The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome.
METHODS:
Thirty-five patients with previously untreated GC were treated with up to six 56-day courses of 110mg/m(2) lomustine on day 1 and 60mg/m(2) procarbazine on days 8 to 21. The primary endpoint was the rate of patients without therapy failure (defined as progressive disease, death from any cause, or termination of PC therapy before the end of course 4) at 8 months after the beginning of PC chemotherapy.
RESULTS:
The failure-free survival rate at 8 months was 50.3%. Median progression-free survival was 14 months. At progression, 12 patients received salvage radiotherapy. Median overall survival was 30 months. Multivariate analysis revealed isocitrate dehydrogenase 1 (IDH1) gene mutation (hazard ratio [HR], 0.11; 95% confidence interval [CI], 0.02-0.58) and initial presentation without a bilateral symmetrical infiltration pattern on magnetic resonance imaging (HR 0.07, 95%CI 0.01-0.54) as independent prognostic factors associated with prolonged survival. IDH1 mutation was significantly associated with MGMT promoter methylation and an oligodendroglial tumor component.
INTERPRETATION:
PC chemotherapy is effective in GC. With the NOA-05 trial being the first prospective multicenter trial in GC, PC chemotherapy can be regarded as a promising option for the primary therapy of these tumors.
AuthorsMartin Glas, Oliver Bähr, Jörg Felsberg, Katja Rasch, Dorothee Wiewrodt, Martin Schabet, Matthias Simon, Horst Urbach, Joachim P Steinbach, Johannes Rieger, Rolf Fimmers, Michael Bamberg, Thomas Nägele, Guido Reifenberger, Michael Weller, Ulrich Herrlinger, Neuro-Oncology Group of the German Cancer Society
JournalAnnals of neurology (Ann Neurol) Vol. 70 Issue 3 Pg. 445-53 (Sep 2011) ISSN: 1531-8249 [Electronic] United States
PMID21710625 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 American Neurological Association.
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Tumor Suppressor Proteins
  • Procarbazine
  • Lomustine
  • DNA Modification Methylases
  • MGMT protein, human
  • DNA Repair Enzymes
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Biomarkers, Tumor (analysis)
  • Brain (pathology)
  • Combined Modality Therapy
  • DNA Modification Methylases (genetics)
  • DNA Repair Enzymes (genetics)
  • Disease Progression
  • Disease-Free Survival
  • Endpoint Determination
  • Female
  • Humans
  • Karnofsky Performance Status
  • Lomustine (administration & dosage)
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neoplasms, Neuroepithelial (drug therapy, pathology, surgery)
  • Procarbazine (administration & dosage)
  • Prognosis
  • Prospective Studies
  • Sample Size
  • Survival Analysis
  • Treatment Outcome
  • Tumor Suppressor Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: